Effects of febuxostat on platelet-derived microparticles and adiponectin in patients with hyperuricema

被引：22

作者：

Nishizawa, Tohru ^{[1
]}

Taniura, Takehito ^{[2
]}

Nomura, Shosaku ^{[1
]}

机构：

[1] Kansai Med Univ, Dept Internal Med 1, Osaka, Japan

[2] Daiwa Hosp, Div Internal Med, Nara, Japan

来源：

BLOOD COAGULATION & FIBRINOLYSIS | 2015年 / 26卷 / 08期

关键词：

adiponectin; febuxostat; hyperuricemia; platelet-derived microparticle; sP-selectin; HIGH-SHEAR-STRESS; OXIDATIVE STRESS; URIC-ACID; NITRIC-OXIDE; INSULIN-RESISTANCE; ALLOPURINOL; PROCOAGULANT; HYPOADIPONECTINEMIA; FAILURE; PROTEIN;

D O I：

10.1097/MBC.0000000000000335

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Platelet-derived microparticles (PDMPs) and adiponectin play an important role in the development of atherothrombosis. We investigated the effect of febuxostat on circulating PDMP levels and adiponectin in hyperuricemic patients. Levels of PDMP and biomarkers were measured using an ELISA at baseline and after 2 and 6 months of treatment. Plasma levels of PDMPs and biomarkers were higher, while those of adiponectin were lower in hyperuricemic patients than in normouricemic controls. Uric acid and interleukin (IL)-6 levels decreased significantly in hyperuricemic patients after 2 months of febuxostat treatment. However, PDMP and biomarkers decreased significantly in hyperuricemic patients after only 6 months of febuxostat treatment and adiponectin increased significantly. These results suggest that the effects of febuxostat for PDMPs seen may be the effect on xanthine oxidase but not the decrease of uric acid, and febuxostat may be beneficial for primary prevention of atherothrombosis in hyperuricemic patients. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.

引用

收藏

页码：887 / 892

页数：6

相关论文

共 38 条

[1]

Uric acid and cardiovascular risk [J].

Alderman, MH .

CURRENT OPINION IN PHARMACOLOGY, 2002, 2 (02) :126-130

[2]

Uric acid and survival in chronic heart failure - Validation and application in metabolic, functional, and Hemodynamic staging [J].

Anker, SD ;

Doehner, W ;

Rauchhaus, M ;

Sharma, R ;

Francis, D ;

Knosalla, C ;

Davos, CH ;

Cicoira, M ;

Shamim, W ;

Kemp, M ;

Segal, R ;

Osterziel, KJ ;

Leyva, F ;

Hetzer, R ;

Ponikowski, P ;

Coats, AJS .

CIRCULATION, 2003, 107 (15) :1991-1997

[3]

Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity [J].

Arita, Y ;

Kihara, S ;

Ouchi, N ;

Takahashi, M ;

Maeda, K ;

Miyagawa, J ;

Hotta, K ;

Shimomura, I ;

Nakamura, T ;

Miyaoka, K ;

Kuriyama, H ;

Nishida, M ;

Yamashita, S ;

Okubo, K ;

Matsubara, K ;

Muraguchi, M ;

Ohmoto, Y ;

Funahashi, T ;

Matsuzawa, Y .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 257 (01) :79-83

[4]

Hyperuricemia as a Mediator of the Proinflammatory Endocrine Imbalance in the Adipose Tissue in a Murine Model of the Metabolic Syndrome [J].

Baldwin, William ;

McRae, Steven ;

Marek, George ;

Wymer, David ;

Pannu, Varinderpal ;

Baylis, Chris ;

Johnson, Richard J. ;

Sautin, Yuri Y. .

DIABETES, 2011, 60 (04) :1258-1269

[5]

Febuxostat compared with allopurinol in patients with hyperuricemia and gout [J].

Becker, MA ;

Schumacher, HR ;

Wortmann, RL ;

MacDonald, PA ;

Eustace, D ;

Palo, WA ;

Streit, J ;

Joseph-Ridge, N .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (23) :2450-2461

[6]

Xanthine oxicloreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications [J].

Berry, CE ;

Hare, JM .

JOURNAL OF PHYSIOLOGY-LONDON, 2004, 555 (03) :589-606

[7]

Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes [J].

Chen, BY ;

Lam, KSL ;

Wang, Y ;

Wu, DH ;

Lam, MC ;

Shen, JG ;

Wong, LC ;

Hoo, RLC ;

Zhang, JL ;

Xu, AM .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 341 (02) :549-556

[8]

Adiponectin stimulates production of nitric oxide in vascular endothelial cells [J].

Chen, H ;

Montagnani, M ;

Funahashi, T ;

Shimomura, I ;

Quon, MJ .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (45) :45021-45026

[9]

Fagugli RM, 2008, CLIN NEPHROL, V70, P523

[10]

Increased oxidative stress in obesity and its impact on metabolic syndrome [J].

Furukawa, S ;

Fujita, T ;

Shimabukuro, M ;

Iwaki, M ;

Yamada, Y ;

Nakajima, Y ;

Nakayama, O ;

Makishima, M ;

Matsuda, M ;

Shimomura, I .

JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (12) :1752-1761

← 1 2 3 4 →